There can't be such a comparison study until one or the other conducts a trial on similar tumor types. I'll go through the protocols again, but from what I can tell the studies so far, and those studies scheduled awaiting Phase 1 completion, the trials so far are different cancers. Unless APR-246 tests with solid tumors, Kevetrin will be first in class for those selective cancer types. IMO, any such comparison study is far away as neither yet seems to be in the other's cancer area.
News 
Market Data 
Discover 
